TTI 621

Drug Profile

TTI 621

Alternative Names: CD47 antigen/SIRPalpha protein modulator - Trillium Therapeutics; SIRPαFc; TTI-621

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator The Hospital for Sick Children; University Health Network
  • Developer Trillium Therapeutics Inc
  • Class Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins
  • Mechanism of Action CD47 antigen inhibitors; SIRPA protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Haematological malignancies; Mycosis fungoides; Solid tumours
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 03 Apr 2017 Efficacy data from a phase I trial in Haematological malignancies presented at the 110th American Association for Cancer Research Annual Meeting (AACR-2017)
  • 24 Feb 2017 Interim pharmacodynamics and immunogenicity data from phase Ia/b trial in haematological malignancies released by Trillium Therapeutics
  • 03 Dec 2016 Efficacy, safety and pharmacokinetics data from a phase I trial in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top